Drug Trial Radar · NCT04925752
Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
3,292
Actual
Start
Jun 28, 2021
Primary completion
Aug 21, 2024
Study completion Aug 2028
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jun 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection. The primary objective of this study is to evaluate the efficacy of LEN for HIV-1 pre-exposure prophylaxis (PrEP) in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth at risk of HIV-1 infection.
Conditions
- Pre-Exposure Prophylaxis of HIV Infection
Interventions
Oral Lenacapavir (LEN)Drug
Tablets administered orally without regard to food
F/TDFDrug
Tablets administered orally
Sub-cutaneous (SC) Lenacapavir (LEN)Drug
Administered via SC injections
Placebo SC LENDrug
Administered via SC injections
PTM F/TDFDrug
Tablets administered orally
PTM Oral LENDrug
Tablets administered orally
F/TAF (for US participants only)Drug
F/TAF tablets administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)Time frame: Incidence Phase Screening Visit (Day 1)
- Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set)Time frame: Up to 149 weeks
Locations
93 sites in 8 countries. Site status is shown where the registry gives one.
UAB Sexual Health Research Clinic
Birmingham, Alabama
Loma Linda University Clinical Trial Center Clinic
Loma Linda, California
Ruane Clinical Research Group Inc.
Los Angeles, California
UCLA CBAM Vine Street Clinic
Los Angeles, California
Charles R. Drew University of Medicine and Science (CDU) - Clinical Translational Research Center (CTRC)
Los Angeles, California
Mills Clinical Research
Los Angeles, California
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Los Angeles, California
BIOS Clinical Research
Palm Springs, California
UCSD Anti Viral Research Center
San Diego, California
Bridge HIV at the San Francisco Department of Public Health
San Francisco, California
Optimus Medical Group
San Francisco, California
University of Colorado Clinical and Translational Research Centers (CTRC)
Aurora, Colorado
Yale University, School of Medicine
New Haven, Connecticut
Whitman-Walker Institute Inc.
Washington D.C., District of Columbia
Washington Health Institute
Washington D.C., District of Columbia
Therafirst Medical Center
Fort Lauderdale, Florida
Gary Richmond, MD, PA
Fort Lauderdale, Florida
Midway Immunology & Research Center, LLC
Ft. Pierce, Florida
CAN Community Health Clinic
Jacksonville, Florida
University of Miami Miller School of Medicine Division of Infectious Disease Research - Converge Miami
Miami, Florida
CAN Community Health
Miami Gardens, Florida
Orlando Immunology Center
Orlando, Florida
CAN Community Health
Sarasota, Florida
The Hope Clinic at Emory University
Atlanta, Georgia
Emory University
Atlanta, Georgia
Emory University Hospital Midtown Infectious Disease Clinic
Atlanta, Georgia
RMR Core Center
Chicago, Illinois
University of Illinois at Chicago, Department of Medicine, Division of Infectious Diseases, Project WISH
Chicago, Illinois
Howard Brown Health Center
Chicago, Illinois
Indiana University Infectious Diseases Research
Indianapolis, Indiana
Baptist Health Lexington
Lexington, Kentucky
Norton Infectious Disease Specialists
Louisville, Kentucky
LSU-CrescentCare Sexual Health Center- New Orleans Community Health Center
New Orleans, Louisiana
Johns Hopkins University School of Medicine
Baltimore, Maryland
The Fenway Institute
Boston, Massachusetts
Be Well Medical Center
Berkley, Michigan
Henry Ford Hospital
Detroit, Michigan
Open Arms Healthcare Center
Jackson, Mississippi
KC CARE Health Center
Kansas City, Missouri
St. Michael's Medical Center
Newark, New Jersey
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.